Millie
your market intelligence analyst
Search Results
429 results
Your search is now limited to «Melanoma» expert search.
LncRNA MAFG-AS1 Accelerates Cell Migration, Invasion and Aerobic Glycolysis of Esophageal Squamous Cell Carcinoma Cells via miR-765/PDX1 Axis.
More from International Journal of COPD:
We focus in melanoma cells, a cancer type where loss of function of the RASSF1A/MST2/LATS1 seems to be common.
More from Molecular Cancer Research - Recent Issues (abstracts):
Frequent GNAQ and GNA11 mutations in uveal melanoma hyperactivate the MEK–ERK signaling pathway, leading to aberrant regulation of cyclin-dependent kinases (CDK) and cell-cycle progression. MEK inhibitors (MEKi) alone show poor efficacy in uveal melanoma, raising the question of whether downstream targets can be vertically inhibited to provide long-term benefit. CDK4/6 selective inhibitors are FDA-approved in patients with estrogen receptor (ER)–positive breast cancer in combination with ER antagonists/aromatase inhibitors. We determined the effects of MEKi plus CDK4/6 inhibitors (CDK4/6i) in uveal melanoma. In vitro , palbociclib, a CDK4/6i, enhanced the effects of MEKi via downregulation of cell-cycle proteins. In contrast, in vivo CDK4/6.
More from Molecular Cancer Therapeutics - Recent Issues (abstracts):
Business Wire 08/03/2020 16:13
Mutated copies of the BRAF V600 protein are found in about half of all melanomas.
More from Business Wire:
Prevalence ratios (PR) and 95% confidence intervals (CI) for the association between tertiles of dietary patterns and melanoma thickness >2 mm versus ≤2 mm were estimated using Poisson regression.
More from Cancer Epidemiology, Biomarkers & Prevention Recent Issues (abstracts):
Purpose:. Brain involvement occurs in the majority of patients with metastatic melanoma. The potential of circulating tumor DNA (ctDNA) for surveillance and monitoring systemic therapy response in patients with melanoma brain metastases merits investigation. Experimental Design:. This study examined circulating BRAF, NRAS , and c-KIT mutations in patients with melanoma with active brain metastases receiving PD-1 inhibitor–based therapy. Intracranial and extracranial disease volumes were measured using the sum of product of diameters, and response assessment performed using RECIST. Longitudinal plasma samples were analyzed for ctDNA over the first 12 weeks of treatment (threshold 2.5 copies/mL plasma). Results:. Of a total of 72 patients, 13 pa.
More from Clinical Cancer Research - Recent Issues (abstracts):
No summary found
More from International Journal of Paediatric Dentistry (EU):
PubMed News (NIH) 08/01/2020
Contributors : Xinyuan Guan ; Liyi Zhang ; Lei Li Series Type : Expression profiling by high throughput sequencing Organism : Homo sapiens. To obtain an accurate overview of changes occurring during fibrocyte-to-cancer associated fibroblast differentiation in human esophageal squamous cell carcinoma (ESCC), we isolated circulating FGFR2+ fibrocytes and their paired FGFR2+ cancer associated fibroblasts (CAFs) from ESCC patients and compared their gene expression profiles by high-throughput RNA Sequencing.
More from PubMed News (NIH):
ClinicalTrials.gov 07/31/2020 06:54
Condition : Melanoma Interventions : Biological: Nivolumab; Biological: Ipilimumab Sponsor : Bristol-Myers Squibb Not yet recruiting.
More from ClinicalTrials.gov:
GlobeNewswire 07/31/2020 02:00
BNT111 has demonstrated clinical anti-tumor activity as a monotherapy and in combination with checkpoint inhibitors in an ongoing Phase 1 trial in patients with advanced melanoma after prior checkpoint blockade.
More from GlobeNewswire:
Healio News 07/30/2020 17:31
FDA approves Tecentriq plus Cotellic and Zelboraf for advanced melanoma.
More from Healio News:
News-Medical.net 07/29/2020 21:19
An international group of melanoma experts, the Melanoma Prevention Working Group, sought to advance conversations around how and when gene expression profiling should be used by clinicians caring for patients with melanoma.
More from News-Medical.net:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications